Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Tapping MCAC For Advice On Technologies Lacking Sufficient Study Data

This article was originally published in The Gray Sheet

Executive Summary

The Medicare Coverage Advisory Committee (MCAC) executive committee will advise CMS on how to review coverage decision requests related to rare conditions for which there is little quality evidence

You may also be interested in...



Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS

CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases

Improved Clinical Outcomes After FDG-PET Diagnosis Key To Coverage – CMS

CMS' decision to deny Medicare coverage of FDG-PET for soft tissue sarcoma and most thyroid cancer indications is consistent with the MCAC recommendation that standards of evidence should not be relaxed for diagnostics of rare diseases

PET coverage

CMS receives formal request for reconsideration of its Dec. 15, 2000 finding of insufficient evidence to support the use of PET for thyroid cancer management. The request, from the American Thyroid Association, includes new information suggesting the usefulness for several thyroid cancer indications. A decision by the Coverage and Analysis group is due Sept. 11

Related Content

UsernamePublicRestriction

Register

MT016788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel